Award & Investment Overview
Ann Arbor-based Blue Arbor Technologies has closed a $10.5 million Series A financing round, led by strategic partner Ottobock, a global prosthetics and wearable bionics company. The investment will support continued development and clinical evaluation of Blue Arbor’s RESTORE Neuromuscular Interface System, designed to improve how people with limb loss control advanced prosthetic devices.
The financing will fund completion of feasibility testing, pursuit of a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) to support clinical studies of the RESTORE External Sensing Unit (ESU), and development of a next-generation Internal Sensing Unit (ISU).
The investment represents an important commercialization milestone as Blue Arbor moves from early human implantation experience toward broader clinical evaluation and product development. The company reports two successful human implantations to date.
Approach & Ecosystem Context
Blue Arbor’s Series A illustrates the role strategic corporate investment can play in advancing research-based medical technologies through the clinical validation and regulatory development stages.
Ottobock’s participation provides more than financial support. As an established prosthetics manufacturer and Blue Arbor’s strategic partner, the company brings relevant industry expertise and a potential pathway for integrating neuromuscular interface technology with advanced prosthetic systems.
The RESTORE platform addresses a commercialization challenge in upper-limb prosthetics: translating complex neuromuscular signals into reliable, intuitive control of multiple prosthetic joints. Moving from promising human implantation results to a commercially viable medical device requires further feasibility testing, clinical evidence, regulatory engagement, and product engineering.
From a Mind the GAP perspective, this financing demonstrates how university-originated or research-based technologies can progress beyond early translational development through strategic industry partnerships and institutional venture investment. The announcement does not identify Blue Arbor’s university affiliations or earlier GAP funding support, so those connections should not be assumed.
The Series A also reflects a shift in commercialization risk. Rather than primarily establishing technical feasibility, Blue Arbor is now pursuing the clinical and product development milestones necessary for potential regulatory authorization and market entry.
Innovation & Technology
RESTORE Neuromuscular Interface System
Blue Arbor Technologies is developing the RESTORE Neuromuscular Interface System to improve control of advanced upper-limb prostheses. The platform is designed to enable independent and simultaneous control of prosthetic fingers, wrists, and elbows, with the goal of providing more responsive and coordinated movement. Blue Arbor is developing two configurations: an External Sensing Unit (ESU) and a fully implantable Internal Sensing Unit (ISU). The company has reported two human implantations and plans additional feasibility and U.S. clinical studies to evaluate the technology’s performance and safety.
Potential Market Uses and Applications
Potential Clinical and Rehabilitation Applications
- Advanced upper-limb prosthetic control for people with limb loss.
- Rehabilitation technologies supporting coordinated prosthetic movement.
- Neuromuscular interfaces for improved prosthetic dexterity and responsiveness.
- Implantable and external sensing systems for prosthetic applications.
Potential Medical Device and Technology Applications
- Integration with advanced prosthetic hands and arms.
- Neuromuscular signal processing and prosthetic control systems.
- Implantable medical device platforms.
- Next-generation human-machine interfaces for assistive technologies.
Potential Commercialization Applications
- Strategic partnerships with prosthetics manufacturers.
- Clinical validation and regulatory development of neuromuscular devices.
- Integration of RESTORE technology into commercial prosthetic systems.
- Development of implantable and external sensing product configurations.
Related Topics
Blue Arbor Technologies, Ottobock, Series A financing, $10.5 million investment, neuromuscular interfaces, RESTORE System, prosthetic control, upper-limb prosthetics, medical device commercialization, strategic corporate investment, medical technology startups, clinical validation, FDA Investigational Device Exemption, implantable medical devices, rehabilitation technology, assistive technology, translational research, venture development, commercialization funding
About innovosource
innovosource tracks GAP programs, including proof-of-concept programs, startup accelerators, translational research initiatives, university venture funds, and commercialization ecosystems that help move university innovations from research to market.
Our coverage is informed by the Mind the GAP Initiative and the GAP COA consortium activity, providing practical insights into the evolving commercialization landscape.
Learn more:
